Mary Wilson
Well-known member
Published: 02 March 2022
https://doi.org/10.1093/ofid/ofac055
Thomas W McDade, Amelia Sancilio, Richard D’Aquila, Brian Mustanski, Lauren A Vaught, Nina L Reiser, Matthew E Velez, Ryan R Hsieh, Daniel T Ryan, Rana Saber,
Elizabeth M McNally, Alexis R Demonbreun
Abstract
Background
Confidence in natural immunity after infection with severe acute respiratory syndrome coronavirus 2 is one reason for vaccine hesitancy.
Methods
We measured antibody-mediated neutralization of spike protein-ACE2 receptor binding in a large community-based sample of seropositive individuals who differed in severity of infection (N = 790).
Results
A total of 39.8% of infections were asymptomatic, 46.5% were symptomatic with no clinical care, 13.8% were symptomatic with clinical care, and 3.7% required hospitalization. Moderate/high neutralizing activity was present after 41.3% of clinically managed infections, in comparison with 7.9% of symptomatic and 1.9% of asymptomatic infections.
Conclusions
Prior coronavirus disease 2019 infection does not guarantee a high level of antibody-mediated protection against reinfection in the general population.
https://academic.oup.com/ofid/article/9/3/ofac055/6541150?searchresult=1&login=false
https://doi.org/10.1093/ofid/ofac055
Thomas W McDade, Amelia Sancilio, Richard D’Aquila, Brian Mustanski, Lauren A Vaught, Nina L Reiser, Matthew E Velez, Ryan R Hsieh, Daniel T Ryan, Rana Saber,
Elizabeth M McNally, Alexis R Demonbreun
Abstract
Background
Confidence in natural immunity after infection with severe acute respiratory syndrome coronavirus 2 is one reason for vaccine hesitancy.
Methods
We measured antibody-mediated neutralization of spike protein-ACE2 receptor binding in a large community-based sample of seropositive individuals who differed in severity of infection (N = 790).
Results
A total of 39.8% of infections were asymptomatic, 46.5% were symptomatic with no clinical care, 13.8% were symptomatic with clinical care, and 3.7% required hospitalization. Moderate/high neutralizing activity was present after 41.3% of clinically managed infections, in comparison with 7.9% of symptomatic and 1.9% of asymptomatic infections.
Conclusions
Prior coronavirus disease 2019 infection does not guarantee a high level of antibody-mediated protection against reinfection in the general population.
https://academic.oup.com/ofid/article/9/3/ofac055/6541150?searchresult=1&login=false
